Anasheh Halabi, MD
Neurology · Los Angeles, CANPI 1689061731
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $26,514 of the $27,695 with a category attached, or 95.7%. 6 manufacturers reported payments, led by Astellas Pharma Global Development at 53.9% of the total. 2025 is the largest year on record at $20,303, more than ten times the $12 reported in 2019.
Across 27 payments — averaging $1025.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma Global Development$15K
- AstraZeneca$6K
- Astrazeneca UK Limited$5K
- Alnylam Pharmaceuticals Inc.$928
- Johnson & Johnson$40
- Takeda Pharmaceuticals U.S.A., Inc.$20
Across 2 payments — averaging $12,975 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$26K
What the payments were for
- Consulting fees$26,51496%
- Travel & lodging$5422%
- Food & beverage$6392%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma Global Development | 10 | $14,915 |
| AstraZeneca(2 entities) | 6 | $6,444 |
| Astrazeneca UK Limited | 7 | $5,348 |
| Alnylam Pharmaceuticals Inc. | 2 | $928 |
| Johnson & Johnson | 1 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,695 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pyridostigmine Bromide | 14 | $1,467 |
| Gabapentin | 85 | $1,221 |
| Pregabalin | 44 | $837 |
| Duloxetine Hcl | 42 | $772 |
| Nortriptyline Hcl | 14 | $188 |
| Amitriptyline Hcl | 12 | $20 |
Paid to pharmacies, not to this prescriber.
Other neurology in Los Angeles
- Perry ShiehLos Angeles$2.4M
- David LiebeskindLos Angeles$1.9M
- John SternLos Angeles$999K
- Jeffrey CummingsLos Angeles$918K
- Alan RapoportLos Angeles$808K
- Alon AvidanLos Angeles$505K
- Mark LewLos Angeles$450K
- Dawn EliashivLos Angeles$364K
- Richard LewisLos Angeles$309K
- Margaret BurnettLos Angeles$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.